A new clinical trial puts a popular glutathione derivative to the test, and the results split cleanly along a line that matters for anyone parsing supplement labels: what S-Acetyl Glutathione (SAG) is sold as doing, and what a controlled study actually measured it doing.
The trial, published in the Journal of Cosmetic Dermatology, enrolled 90 participants with Fitzpatrick skin types IV and V and randomized them into three arms over 12 weeks: oral SAG at 200 mg per day, reduced glutathione at 500 mg per day, or placebo. Researchers led by Arie Kusumawardani tracked melanin index using Mexameter readings as the primary outcome, with transepidermal water loss (TEWL), facial skin analyzer pigmentation scores, and patient and physician satisfaction ratings as secondary measures.
SAG is marketed on the premise that acetylating glutathione improves cellular uptake and stability compared to the reduced form, which degrades quickly in the gut and bloodstream. That formulation argument is about bioavailability, not about a different mechanism of action against melanin itself. Reduced glutathione already has a research record as a tyrosinase inhibitor; SAG's pitch is that more of it survives to reach skin cells.
On the study's primary endpoint, that pitch held up: SAG produced a significantly faster reduction in melanin index than both reduced glutathione and placebo. TEWL, a marker of skin barrier function, also showed significant between-group differences by Week 8 and Week 12, and both patient and physician satisfaction scores favored active treatment over placebo.
The gaps are where the ingredient story gets more cautious. None of the three groups, including SAG, showed statistically significant pigmentation reduction on facial skin analyzer measurements, a different instrument than the Mexameter used for the primary endpoint. And total glutathione (GSH) levels, the exploratory marker meant to confirm the compound was actually raising systemic glutathione, did not differ significantly between groups at all.
That last finding is the one marketing claims tend to skip. A supplement advertised as boosting glutathione levels, in this trial, failed to demonstrate a measurable rise in glutathione compared to placebo, even as its effect on melanin index was strong enough to reach statistical significance. The authors' own conclusion acknowledges the split directly, crediting SAG with faster melanin index acceleration while flagging that the absence of significant pigmentation reduction and GSH change "should be noted."
For a reader comparing bioavailability claims against what a Mexameter and a glutathione assay actually recorded, the trial offers a narrow but real result: SAG reduced melanin index faster than reduced glutathione over 12 weeks in Fitzpatrick IV and V skin. It does not, on this data, establish that the compound raises circulating glutathione or reduces pigmentation as measured by a facial skin analyzer. The authors call for longer-term studies in broader populations before either gap closes.
